<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VIDARABINE</span><br/>(vye-dare'a-been)<br/><span class="topboxtradename">Adenine Arabinoside, </span><span class="topboxtradename">ARA-A, </span><span class="topboxtradename">Vira-A<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Zidovudine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>3% ointment</p>
<h1><a name="action">Actions</a></h1>
<p>A pyrimidine nucleoside obtained from <i>Streptomyces antibioticus</i>. Mechanism of action is not known but appears to block early stages of DNA synthesis by inhibiting DNA polymerase.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Active against herpes simplex virus types 1 and 2, varicella zoster, vaccinia, cytomegalovirus, hepatitis B virus, and Epstein-Barr
         virus. Not active against smallpox, adenovirus, DNA or RNA viruses, bacteria, and fungi.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Used topically (ophthalmic) for treatment of acute keratoconjunctivitis and recurrent epithelial keratitis caused by herpes
         simplex virus types 1 and 2. Topical antibiotics and topical corticosteroids may be used concurrently.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safe use during pregnancy (category C) and lactation is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney or liver function; patients susceptible to fluid overload or cerebral edema.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Herpes Keratitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span> Instill 1 cm (½ in.) ribbon of ointment into lower conjunctival sac q3h 5 times/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Instillation</span><br/><ul>
<li>Instill ribbon of ointment into lower conjunctival sac as prescribed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Special Senses:</span> Burning, itching, mild irritation, lacrimation, foreign body sensation, pain, photophobia, punctal occlusion, superficial
      punctate keratitis. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Widely distributed in body tissues and fluid; crosses bloodbrain barrier; trace amounts of ophthalmic application found
      in aqueous humor; crosses placenta. <span class="typehead">Metabolism:</span> Rapidly deaminated to ara-hypoxanthine (Ara-Hx), a less active metabolite. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 1.5 h vidarabine, 3.3 h Ara-Hx. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not exceed recommended dose, frequency, and duration of treatment.</li>
<li>Wash hands before and after treatment.</li>
<li>Vision may be temporarily hazy following instillation; avoid potentially hazardous activities until vision clears.</li>
<li>Use sunglasses as necessary; drug may cause sensitivity to bright light.</li>
<li>Do not breast feed while using this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>